Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration Resistant Prostate Cancer 1 Breast Neoplasms 1

Interventions

pembrolizumab 163 Carboplatin 146 Paclitaxel 125 Cyclophosphamide 94 130-nm albumin-bound paclitaxel 66 Capecitabine 64 Gemcitabine 54 Doxorubicin 50 Albumin-Bound Paclitaxel 45 Taxes 42 atezolizumab 41 Cisplatin 39 sacituzumab govitecan 34 Nivolumab 34 olaparib 32 Epirubicin 32 Specimen Handling 28 Docetaxel 28 eribulin 27 Bevacizumab 26 durvalumab 25 Drug Therapy 25 Biopsy 24 camrelizumab 23 Magnetic Resonance Spectroscopy 22 toripalimab 19 Radiotherapy 17 spartalizumab 16 Everolimus 15 veliparib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × sabizabulin × Clear all

NCT05008510 2022-02-08

VERU-111

Veru Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡